Eli Lilly's Dominance in the Weight Loss Drug Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 9 hours ago
0mins
Source: Fool
- Market Share Growth: Eli Lilly has captured 60% of the U.S. GLP-1 drug market and 53% internationally, further solidifying its leadership position by launching the new oral weight loss drug Foundayo, which is expected to drive future sales growth.
- Surge in Sales: In the recent quarter, Lilly's weight loss products generated over $12 billion in sales, contributing to an overall sales increase of 56%, demonstrating its strong performance and profitability in the rapidly growing weight loss drug market.
- Promising R&D Pipeline: Lilly's robust pipeline in the weight loss drug sector includes the promising candidate retatrutide, currently in phase 3 trials, which has shown significant weight loss effects and is expected to provide strong support for the company's future growth.
- Evolving Competitive Landscape: While Lilly faces competition from companies like Viking Therapeutics, the strong demand for weight loss drugs indicates ample market space for multiple successful players, allowing Lilly to likely maintain its dominant market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to fall
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1235.560
Low
950.00
Averages
1192
High
1500
Current: 1235.560
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Stock Soars to All-Time High Amid GLP-1 Drug Success
- Significant Stock Surge: Eli Lilly's stock has skyrocketed from around $850 in late April to over $1,200, marking a more than 40% increase, which not only sets a new 52-week high but also an all-time high, reflecting strong market confidence in its growth potential.
- Market Capital Recovery: The surge in stock price has propelled Eli Lilly's market capitalization back above the $1 trillion mark, indicating optimistic investor expectations for its future performance and further solidifying its leadership position in the pharmaceutical industry.
- Remarkable Earnings Growth: The company reported a staggering 56% growth rate in the first quarter, the highest in the past decade, primarily driven by the successful rollout of its GLP-1 drugs, Mounjaro and Zepbound, showcasing its robust performance in the new drug market.
- Optimistic Future Outlook: Despite the high current stock price, Eli Lilly is still considered a quality investment, with analysts projecting continued growth in profitability, prompting investors to carefully consider a long-term holding strategy to navigate potential market fluctuations.
See More
Eli Lilly's Promising Future in Obesity Drug Market
- Market Growth Potential: Research from Morgan Stanley estimates that the obesity drug market will surge from approximately $15 billion in 2024 to $150 billion by 2035, indicating strong growth potential for Eli Lilly over the next decade.
- New Drug Launch Impact: Eli Lilly launched its first oral obesity drug, Foundayo, in the U.S. in April 2023, becoming the second oral medication on the market, which is expected to attract more patients and further increase the company's market share in obesity treatments.
- Clinical Trial Results: Eli Lilly's Retatrutide, a next-generation subcutaneous triple-receptor agonist currently in late-stage clinical trials, has shown strong weight-loss results, and if approved, could lead to significant sales growth for the company.
- Earnings Expectations: Analysts project Eli Lilly's earnings will grow at an average rate of 22% annually over the next three to five years, and even with a conservative estimate of 15%, the earnings per share could reach $35.60 by 2036, suggesting a potential stock price increase of 158%, providing substantial returns for investors.
See More
The Importance of a Long-Term Investment Framework
- Investment Framework Shift: Long-term investing necessitates a different framework that emphasizes the ability to anticipate and adapt to future market changes, thereby enhancing the effectiveness and accuracy of investment decisions.
- Price Reference Timing: The stock prices referenced were the afternoon prices from July 5, 2026, reflecting the market's state at a specific point in time, which aids investors in understanding the context of market fluctuations.
- Video Release Timing: The video was published on July 7, 2026, providing an in-depth analysis of investment strategies aimed at helping investors make informed decisions in a complex market environment.
- Importance of Long-Term Perspective: It underscores the necessity of adopting a long-term perspective in investment decisions, focusing not only on short-term gains but also on long-term growth potential to achieve sustainable investment returns.
See More
Investing for the Long Run Requires a New Framework
- Investment Signal Resurgence: In 2009, Nvidia flashed a 'Double Down' signal, and now the same 'Total Conviction' signal is appearing for a company that is only 1/100th the size of Nvidia, indicating potential new investment opportunities in the market.
- Recommended Stocks Performance: The Motley Fool Stock Advisor team has identified 10 stocks that could yield significant returns in the coming years, notably excluding Coca-Cola, which reflects a market reassessment of traditional brands.
- Historical Return Comparison: An investment of $1,000 in Netflix on December 17, 2004, would have grown to $410,833, while an investment in Nvidia would have reached $1,208,693, demonstrating the substantial investment value of Stock Advisor's recommendations.
- Superior Market Performance: With a total average return of 917%, Stock Advisor significantly outperforms the S&P 500's 209%, indicating that its stock selection strategy is exceptionally effective and warrants investor attention.
See More
Eli Lilly's Dominance in the Weight Loss Drug Market
- Market Share Growth: Eli Lilly has captured 60% of the U.S. GLP-1 drug market and 53% internationally, further solidifying its leadership position by launching the new oral weight loss drug Foundayo, which is expected to drive future sales growth.
- Surge in Sales: In the recent quarter, Lilly's weight loss products generated over $12 billion in sales, contributing to an overall sales increase of 56%, demonstrating its strong performance and profitability in the rapidly growing weight loss drug market.
- Promising R&D Pipeline: Lilly's robust pipeline in the weight loss drug sector includes the promising candidate retatrutide, currently in phase 3 trials, which has shown significant weight loss effects and is expected to provide strong support for the company's future growth.
- Evolving Competitive Landscape: While Lilly faces competition from companies like Viking Therapeutics, the strong demand for weight loss drugs indicates ample market space for multiple successful players, allowing Lilly to likely maintain its dominant market position.
See More
Major US Biopharmaceutical Companies Expected to Underperform in H2
- Industry Performance Outlook: Major US biopharmaceutical companies are expected to underperform in the second half of the year, reflecting challenges and uncertainties that may impact investor confidence.
- Market Reaction: Increased investor focus on the biopharmaceutical sector could lead to heightened volatility in related stocks, resulting in downward pressure on share prices in the short term.
- Policy Impact: Uncertainties in industry policy changes and regulatory environments may exacerbate performance fluctuations, affecting long-term strategic planning and investment decisions for companies.
- Intensifying Competition: The rise of emerging biotech firms poses greater competitive pressure on traditional biopharmaceutical companies, necessitating accelerated innovation and R&D investments to maintain market share.
See More
Eli Lilly's Stock Soars to All-Time High Amid GLP-1 Drug Success
- Significant Stock Surge: Eli Lilly's stock has skyrocketed from around $850 in late April to over $1,200, marking a more than 40% increase, which not only sets a new 52-week high but also an all-time high, reflecting strong market confidence in its growth potential.
- Market Capital Recovery: The surge in stock price has propelled Eli Lilly's market capitalization back above the $1 trillion mark, indicating optimistic investor expectations for its future performance and further solidifying its leadership position in the pharmaceutical industry.
- Remarkable Earnings Growth: The company reported a staggering 56% growth rate in the first quarter, the highest in the past decade, primarily driven by the successful rollout of its GLP-1 drugs, Mounjaro and Zepbound, showcasing its robust performance in the new drug market.
- Optimistic Future Outlook: Despite the high current stock price, Eli Lilly is still considered a quality investment, with analysts projecting continued growth in profitability, prompting investors to carefully consider a long-term holding strategy to navigate potential market fluctuations.
See More
Eli Lilly's Promising Future in Obesity Drug Market
- Market Growth Potential: Research from Morgan Stanley estimates that the obesity drug market will surge from approximately $15 billion in 2024 to $150 billion by 2035, indicating strong growth potential for Eli Lilly over the next decade.
- New Drug Launch Impact: Eli Lilly launched its first oral obesity drug, Foundayo, in the U.S. in April 2023, becoming the second oral medication on the market, which is expected to attract more patients and further increase the company's market share in obesity treatments.
- Clinical Trial Results: Eli Lilly's Retatrutide, a next-generation subcutaneous triple-receptor agonist currently in late-stage clinical trials, has shown strong weight-loss results, and if approved, could lead to significant sales growth for the company.
- Earnings Expectations: Analysts project Eli Lilly's earnings will grow at an average rate of 22% annually over the next three to five years, and even with a conservative estimate of 15%, the earnings per share could reach $35.60 by 2036, suggesting a potential stock price increase of 158%, providing substantial returns for investors.
See More
The Importance of a Long-Term Investment Framework
- Investment Framework Shift: Long-term investing necessitates a different framework that emphasizes the ability to anticipate and adapt to future market changes, thereby enhancing the effectiveness and accuracy of investment decisions.
- Price Reference Timing: The stock prices referenced were the afternoon prices from July 5, 2026, reflecting the market's state at a specific point in time, which aids investors in understanding the context of market fluctuations.
- Video Release Timing: The video was published on July 7, 2026, providing an in-depth analysis of investment strategies aimed at helping investors make informed decisions in a complex market environment.
- Importance of Long-Term Perspective: It underscores the necessity of adopting a long-term perspective in investment decisions, focusing not only on short-term gains but also on long-term growth potential to achieve sustainable investment returns.
See More
Investing for the Long Run Requires a New Framework
- Investment Signal Resurgence: In 2009, Nvidia flashed a 'Double Down' signal, and now the same 'Total Conviction' signal is appearing for a company that is only 1/100th the size of Nvidia, indicating potential new investment opportunities in the market.
- Recommended Stocks Performance: The Motley Fool Stock Advisor team has identified 10 stocks that could yield significant returns in the coming years, notably excluding Coca-Cola, which reflects a market reassessment of traditional brands.
- Historical Return Comparison: An investment of $1,000 in Netflix on December 17, 2004, would have grown to $410,833, while an investment in Nvidia would have reached $1,208,693, demonstrating the substantial investment value of Stock Advisor's recommendations.
- Superior Market Performance: With a total average return of 917%, Stock Advisor significantly outperforms the S&P 500's 209%, indicating that its stock selection strategy is exceptionally effective and warrants investor attention.
See More
Eli Lilly's Dominance in the Weight Loss Drug Market
- Market Share Growth: Eli Lilly has captured 60% of the U.S. GLP-1 drug market and 53% internationally, further solidifying its leadership position by launching the new oral weight loss drug Foundayo, which is expected to drive future sales growth.
- Surge in Sales: In the recent quarter, Lilly's weight loss products generated over $12 billion in sales, contributing to an overall sales increase of 56%, demonstrating its strong performance and profitability in the rapidly growing weight loss drug market.
- Promising R&D Pipeline: Lilly's robust pipeline in the weight loss drug sector includes the promising candidate retatrutide, currently in phase 3 trials, which has shown significant weight loss effects and is expected to provide strong support for the company's future growth.
- Evolving Competitive Landscape: While Lilly faces competition from companies like Viking Therapeutics, the strong demand for weight loss drugs indicates ample market space for multiple successful players, allowing Lilly to likely maintain its dominant market position.
See More
Major US Biopharmaceutical Companies Expected to Underperform in H2
- Industry Performance Outlook: Major US biopharmaceutical companies are expected to underperform in the second half of the year, reflecting challenges and uncertainties that may impact investor confidence.
- Market Reaction: Increased investor focus on the biopharmaceutical sector could lead to heightened volatility in related stocks, resulting in downward pressure on share prices in the short term.
- Policy Impact: Uncertainties in industry policy changes and regulatory environments may exacerbate performance fluctuations, affecting long-term strategic planning and investment decisions for companies.
- Intensifying Competition: The rise of emerging biotech firms poses greater competitive pressure on traditional biopharmaceutical companies, necessitating accelerated innovation and R&D investments to maintain market share.
See More
